Tag: IN.PACT Admiral DCB

Episode 4: Real world data show IN.PACT Admiral DCB is “very...

 In this penultimate episode of a special five-part series on the history of drug-coated balloons (DCBs), Jos van den Berg (Lugano, Switzerland) is joined...

BIOPACT head-to-head non-inferiority randomised controlled trial completes enrolment

Biotronik is proud to announce the completion of enrolment of the investigator-initiated BIOPACT randomised controlled trial (RCT). This non-inferiority study evaluates the safety and...

Episode 3: The unique recipe for long-term clinical benefit with IN.PACT™...

In this third episode of a special five-part series on the history of DCBs, Jos van den Berg (Lugano, Switzerland) moderates a Vascular News roundtable discussion...

Lower-dose SurVeil DCB achieves non-inferiority with IN.PACT Admiral balloon

 Kenneth Rosenfield (Boston, USA) speaks to Vascular News about the TRANSCEND trial, a non-inferiority randomised controlled trial, which looked to demonstrate safety and efficacy of the...

Safety and efficacy of IN.PACT Admiral sustained out to five years

In a late-breaking data session at this year’s Vascular Interventional Advances conference (VIVA 2020; 6–8 November, virtual) Thomas Zeller (University Heart Center Freiburg, Bad...

Directional atherectomy prior to IN.PACT DCB effective out to one year,...

A vessel preparation treatment strategy of directional atherectomy prior to drug-coated balloon angioplasty with Medtronic’s IN.PACT Admiral drug-coated balloon (DCB) in long, calcified femoropoliteal...
AV access

VIVA 2019: Four-year data from the IN.PACT Global study highlight durable...

Medtronic today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT Admiral drug-coated balloon (DCB)...

Revised safety analysis of Medtronic’s IN.PACT Admiral DCB published in JACC

Medtronic has issued the following statement regarding revised clinical study data: On 15 February, 2019, Medtronic issued a statement regarding a programming error in the...
Medtronic

Medtronic revises IN.PACT post-market study data due to programming error, but...

Medtronic has issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the clinical data reporting isolated...
Japanese

Three-year Japanese results show IN.PACT Admiral DCB offers “consistent and durable”...

The IN.PACT Admiral drug-coated balloon (DCB; Medtronic) exhibits a consistent and durable treatment effect in “a more complex patient demographic than typically seen in...

Live from CIRSE 2018: Three-year results from global study confirm the...

The largest prospective, independently-adjudicated study of drug coated balloons (DCBs) in a broad range of lesions in real-world patients confirms the safety and performance...

Medtronic receives US FDA clearance for 200mm and 250mm IN.PACT Admiral...

Medtronic has announced that it has received US FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral drug-coated balloon (DCB) to treat...